Ticker brief
CRDL
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
13
authors 14d
2
crowd 14d
+0.49
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.40 (−1 bearish … +1 bullish)
Who spoke2
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Gantosj | B | +2.48 | 9 | +0.54 |
| @cdntradegrljenn | C | +0.62 | 4 | +0.50 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @cdntradegrljenn | +0.40 | B. Riley initiates CRDL at Buy with an $11 target and cites clinical catalysts. | · | tweet ↗ |
| 2026-08-27 | @Gantosj | +0.15 | Provides Phase 3 enrollment and topline-data timing for CRDL's recurrent pericarditis study. | · | tweet ↗ |
| 2026-08-26 | @cdntradegrljenn | +0.55 | Reports CRDL shorts being squeezed by the day's price action. | · | tweet ↗ |
| 2026-08-26 | @Gantosj | +0.75 | Argues Lilly's $3.2B Ventyx acquisition validates CRDL's field and could drive revaluation or a deal. | · | tweet ↗ |
| 2026-08-26 | @Gantosj | +0.25 | Tracks CRDL's first test of $2.08 resistance and awaits a close above it to confirm breakout. | · | tweet ↗ |
| 2026-08-26 | @Gantosj | +0.65 | Argues CRDL's oral therapy and publications increasingly de-risk its phase-three program. | · | tweet ↗ |
| 2026-08-26 | @Gantosj | +0.40 | B. Riley initiates CRDL coverage with a Buy rating and $11 price target. | · | tweet ↗ |
| 2026-08-25 | @cdntradegrljenn | +0.40 | Expresses approval of CRDL alongside a chart image | · | tweet ↗ |
| 2026-08-25 | @Gantosj | +0.70 | Describes resumed upside momentum after key breakouts and sets targets at 2.08 and 2.36. | · | tweet ↗ |
| 2026-08-24 | @Gantosj | +0.55 | Expresses confidence in CRDL's scientific rationale and awaits Phase 3 milestones. | · | tweet ↗ |
| 2026-08-20 | @cdntradegrljenn | +0.65 | Bullish comparison highlights CRDL's trial progress and KNSA's $6B valuation. | · | tweet ↗ |
| 2026-08-20 | @Gantosj | +0.65 | Identifies $2.08 as Cardiol's next breakout level and cites surging volume as possible institutional participation. | · | tweet ↗ |
| 2026-08-17 | @Gantosj | +0.75 | CRDL's next target is resistance at $2.08. — Bullish price action and drug potential support an explicit $2.08 target. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.